Hyperuricaemia and Gout Pathway
Five ways in: the raised urate, the acute flare, urate lowering, tumour lysis, stones · v11. What Is the Situation?
2. Patient
3. Laboratory
4. Comorbidities
Renal and Transplant5. Current Medication
Tick what the patient is actually taking. Six of these change the dose, three of them make a drug on this page unsafe, and two of them are the reason the urate is high in the first place.
Evidence & Clinical Pearls
1. The Prescription This Tool Exists to Interrupt
A urate of 8.6 mg/dL appears on a health check panel. The patient has never had a swollen joint. Allopurinol 100 mg or febuxostat 40 mg is written, and nobody revisits it for a decade. That sequence is the single commonest use of urate-lowering therapy that no guideline anywhere describes as standard care, and it is worth understanding why the international bodies have taken such different views of it rather than simply being told which one to follow.
The American College of Rheumatology conditionally recommends against starting any urate-lowering drug for asymptomatic hyperuricaemia, and it grades the certainty of that evidence as high. The number it quotes is the one to remember: 24 patients would need to be treated for three years to prevent a single first gout flare. The European recommendations do not address asymptomatic hyperuricaemia at all, which is different from opposing it. The Japanese guideline says drug therapy may be considered above 9.0 mg/dL without a comorbidity and above 8.0 mg/dL with one, and the Chinese consensus arrives at almost exactly the same pair of thresholds, 540 and 480 micromol per litre, by an independent route.
What makes the Japanese position more interesting than the threshold table suggests is that its own graded recommendations are narrower than the table. Of the comorbidities, only renal impairment carries a positive graded recommendation for urate-lowering drugs, and that one is conditional on moderate evidence. For hypertension and for heart failure the guideline says urate-lowering drugs cannot be positively recommended. What it does recommend, with a grade, is dietary and lifestyle guidance. So the widely repeated shorthand that Japan treats asymptomatic hyperuricaemia with drugs is a simplification of a document that is considerably more cautious than that.
2. What Each Guideline Would Do With the Same Patient
| Guideline | Asymptomatic hyperuricaemia | After a first flare | Serum urate target |
|---|---|---|---|
| ACR 2020 (United States) | Conditionally against any drug, high certainty | Conditionally against, unless CKD stage 3 or worse, urate above 9 mg/dL, or urolithiasis | Below 6 mg/dL, strong. Declines to set a lower target for severe disease |
| EULAR 2016 (Europe) | Silent. Every recommendation is framed around established gout | Discuss from first presentation. Initiate if under 40 years, urate above 8 mg/dL, or comorbidity | Below 6 mg/dL, and below 5 mg/dL for tophaceous or severe disease until crystals dissolve. Never below 3 mg/dL long term |
| ACP 2017 (United States, physicians) | Not addressed | Strongly against long-term therapy after a first attack or with infrequent attacks | No target. Holds that the evidence is insufficient to show that treating to a target outweighs the harms of repeated monitoring and escalation |
| APLAR 2021 (Asia-Pacific, with Indian authors) | Strongly against urate-lowering therapy in hypertension to reduce cardiovascular events | Suggests starting therapy in newly diagnosed gout with urate 9 mg/dL or above | Treat to target, with low-dose colchicine 1.5 to 1.8 mg daily as prophylaxis while starting |
| Japan 2019, third edition | Consider a drug above 9.0 mg/dL, or above 8.0 with a comorbidity, aiming for 6.0 or below. Graded support only for renal impairment. Against in hypertension and heart failure | Treat established gout in the usual way | 6.0 mg/dL or below |
| China 2017 consensus | Start above 540 micromol per litre with no comorbidity, above 480 with one | Start after one attack if any of age under 40, tophi, stones, renal impairment, hypertension, diabetes, dyslipidaemia, obesity or vascular disease | Below 360 micromol per litre, below 300 in severe disease, never below 180 |
Two things are worth noticing in that table. The first is that the disagreement is not about the data. Every one of these bodies read broadly the same literature; they differ on how much evidence a recommendation needs before it is made, which is a judgement about evidentiary thresholds rather than about uric acid. The second is that the East Asian guidelines and the Western ones diverge most sharply exactly where the evidence is thinnest, which is the untreated patient who has never had a flare.
3. Does a High Urate Damage the Heart or the Kidney?
The observational association is real and consistent: a meta-analysis of 17 prospective studies covering 166,486 people and 9,784 coronary events found an odds ratio of 1.07 for each standard deviation increase in urate. The question is whether the urate is doing the damage or merely marking it, and two lines of evidence bear on that.
The first is Mendelian randomisation, which uses inherited variants that raise urate as a natural randomisation. The signal shrinks towards nothing as the instruments are cleaned of pleiotropy: the conventional estimate gives an odds ratio of 1.18, the multivariable-adjusted estimate 1.10, and the MR-Egger estimate, which corrects for pleiotropy at the cost of power, gives 1.05 with a confidence interval from 0.92 to 1.20. A second study using variants specific to urate found no clinically relevant causal effect on coronary disease, myocardial infarction or stroke, with ischaemic stroke at exactly 1.00.
The second is the randomised trials, and there are now three large ones in people without gout. ALL-HEART gave allopurinol up to 600 mg daily to 5,937 patients aged 60 and over with ischaemic heart disease: the composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death occurred in 11.0 per cent against 11.3 per cent, a hazard ratio of 1.04, and the authors concluded that allopurinol should not be recommended for secondary prevention. CKD-FIX gave allopurinol to 363 adults with stage 3 or 4 chronic kidney disease for two years and found the rate of decline in estimated GFR identical between arms. PERL did the same in 530 people with type 1 diabetes and albuminuria and found no clinically meaningful benefit on measured GFR.
Against those sits FREED, in 1,070 Japanese patients aged 65 and over with a urate between 7.0 and 9.0 mg/dL and a comorbidity. Febuxostat reduced a composite endpoint from 28.7 to 23.3 per cent, hazard ratio 0.750. Read the components before quoting it: the only individually significant one was renal impairment, and the comparator arm received allopurinol whenever the urate rose. The honest summary is that urate lowering has not been shown to prevent cardiovascular events and should not be offered for that purpose, and that the renal question is not fully closed but the weight of randomised evidence is against a clinically meaningful effect.
4. The Flare Is a Clinical Diagnosis Until the Joint Is Aspirated
EULAR 2018 is unambiguous: a search for crystals in synovial fluid or a tophus aspirate is recommended in every person with suspected gout, and it is strongly recommended in any patient with undiagnosed inflammatory arthritis. Where that is not feasible, the features that support a clinical diagnosis are named: a single foot or ankle joint, especially the first metatarsophalangeal, previous similar episodes, pain and swelling at their worst within 24 hours, erythema, male sex, and associated cardiovascular disease and hyperuricaemia.
Two negative statements from that document matter more than the positive ones. The diagnosis of gout should not be made on hyperuricaemia alone. And the serum urate has limited diagnostic value during a flare: roughly 10 per cent of people with gout have a urate below 6 mg/dL while the joint is inflamed. The 2015 classification criteria go further and specify that the urate used for scoring should be taken off urate-lowering treatment and beyond four weeks from the start of an episode.
The 2015 ACR/EULAR criteria classify; they do not diagnose. They were built to select homogeneous populations for trials and were deliberately weighted towards specificity, which means a score below 8 does not exclude gout in the patient in front of you. This tool prints the score because it organises the findings usefully, and prints that caution every time it does so.
5. Crystals Do Not Exclude Sepsis
This is the miss that costs a joint or a life, and it is a miss precisely because the aspirate came back positive. In a hospital database series covering 1,116 patients with crystal-induced arthritis between 2015 and 2024, 45 of them, 4 per cent, had concomitant septic arthritis. Monosodium urate crystals were present in 80 per cent of those cases. Fever was present in 95.6 per cent, the median synovial white cell count was 61,478 per microlitre, and mortality was 15.6 per cent. Older series report coexistence between 1.5 and 5.2 per cent, so the figure is not an outlier.
No synovial white cell threshold rules sepsis out. A count above 100,000 has a specificity of 93 to 100 per cent but a sensitivity of only 13 to 40 per cent, and a proportion of at least 90 per cent polymorphs performs poorly in both directions. A count of 30,000 in a patient with proven gout does not exclude a septic joint. Practice advisory: every flare aspirate goes for Gram stain and culture as well as polarised microscopy, and fever with a high count and a high C-reactive protein is treated as sepsis until the cultures are back, whatever the crystals show.
6. Colchicine, the 0.5 mg Tablet, and the Drugs That Make It Dangerous
Every dose in the American literature is built on a 0.6 mg tablet. Indian colchicine is supplied as 0.5 mg. That single fact makes the standard American regimen, 1.2 mg then 0.6 mg an hour later, undeliverable here, because no source endorses two and a half tablets. It also makes the renal and interaction doses, which are 0.3 mg, impossible to reproduce without quartering a tablet.
The way out is that EULAR wrote its regimen in the units India actually stocks: colchicine within 12 hours of onset, 1 mg loading, then 0.5 mg one hour later, which is two tablets and then one. That is a quotation, not a conversion. The evidence behind low-dose colchicine is a randomised dose comparison in which 1.8 mg given over an hour and 4.8 mg given over six hours produced the same response rate at 24 hours, 38 against 33 per cent, while diarrhoea fell from 77 per cent to 23 per cent. Always write the milligrams, never the number of tablets.
Three interactions matter and the sources disagree on how hard to state them. The American label permits a reduced colchicine dose alongside a strong CYP3A4 or P-glycoprotein inhibitor; EULAR says colchicine should not be given to a patient on ciclosporin or clarithromycin. In a resident-facing tool the European rule is the safer one and is the one applied here. The label carries one instruction that both agree on and that settles the transplant patient with graft dysfunction: patients with renal or hepatic impairment should not be given colchicine together with a P-glycoprotein or strong CYP3A4 inhibitor at all. Statins and fibrates independently potentiate colchicine myopathy, which is a slow, painless, creeping proximal weakness that is routinely attributed to something else.
7. Treat to Target, and the Case Against It
The rationale is physical rather than statistical. Monosodium urate crystallises out of solution above roughly 6.8 mg/dL at body temperature, so holding the serum urate below 6 mg/dL keeps the tissue pool undersaturated and existing crystal deposits dissolve. The ACR grades treating to a target below 6 mg/dL as a strong recommendation, and grades the strategy of titrating by serial measurements over fixed dosing as strong as well.
The American College of Physicians reached the opposite conclusion from the same literature, and its reasoning deserves to be stated properly rather than dismissed. It found the evidence insufficient to conclude that the benefits of escalating therapy to reach a urate target outweigh the harms of repeated monitoring and medication escalation, and it noted that no experimental study has compared the health outcomes of treating to one serum urate level against another. Its alternative is to escalate therapy on the basis of symptoms and to stop measuring. Nobody has run the trial that would settle it.
Where this bites in Indian practice is not the philosophy but the follow-up. A treat-to-target strategy requires a urate every two to four weeks during titration and then twice a year for life. Where that follow-up will not happen, a titration plan that assumes it is a plan that will leave the patient on 100 mg of allopurinol indefinitely, which is the dose least likely to reach target and equally likely to provoke the flares that make patients stop the drug.
8. Allopurinol: Start Low, Titrate Without a Ceiling
Two separate ideas used to be confused, and separating them is the most useful thing a resident can take from this section. The starting dose is low because a high starting dose is a risk factor for allopurinol hypersensitivity syndrome: 100 mg daily at most, and 50 mg in chronic kidney disease stage 3 or worse. The maintenance dose is whatever reaches the target, and restricting it by creatinine clearance has no evidence behind it.
The trial that established this randomised 183 people with gout, over half of whom had a creatinine clearance below 60 mL/min, to continue at a clearance-based dose or to escalate. At 12 months, 69 per cent of the escalation group were below 6 mg/dL against 32 per cent of the controls, with mean doses of 413 and 288 mg daily. Serious adverse events were comparable, and there were no cases of allopurinol hypersensitivity syndrome in either arm. At 24 months, target was reached by 64.3 per cent of those with a clearance below 30 mL/min, 76.4 per cent between 30 and 60, and 75.0 per cent above 60, differences that were not significant. Only 2 of the 14 patients with a clearance below 30 who reached target needed more than 300 mg daily.
There is a live disagreement here. EULAR still caps the allopurinol maximum by creatinine clearance and switches agent if target is not reached; the ACR keeps allopurinol first-line in chronic kidney disease and titrates past that cap. The randomised evidence supports the American position, and this tool follows it while saying so.
Allopurinol hypersensitivity is not common but it is not survivable in a proportion of cases. Across 901 published cases from 1950 to 2012, all-cause mortality was 14 per cent, renal impairment was present in 48 per cent and concomitant diuretics in 45 per cent, and about 90 per cent of reactions appeared within 60 days of starting. Any rash on allopurinol means the drug stops that day, permanently, and is not rechallenged.
9. HLA-B*58:01, and What Is and Is Not Known in India
The association is one of the strongest drug-genotype associations described: pooled odds ratios of 96.6 in matched-control studies and 79.3 in population-control studies. The ACR conditionally recommends testing before allopurinol in patients of Southeast Asian descent, naming Han Chinese, Korean and Thai, and in African American patients, quoting prevalences of 7.4 and 3.8 per cent against 0.7 per cent in white and Hispanic populations. South Asians are not named in that recommendation. APLAR states the rule generically instead: test where the population prevalence of the allele is 5 per cent or more.
There is now a large Indian dataset. Allele frequencies for HLA-B*58:01 in 130,518 registered Indian stem cell donors across eight linguistic populations run from 3.20 per cent in Bengali to 6.87 per cent in Malayalam speakers, with Kannada speakers second at 5.54 per cent. These are allele frequencies, not carrier frequencies. The proportion of people carrying at least one copy is roughly twice that, in the region of 6 to 13 per cent. On that basis several Indian populations, and the southern ones in particular, sit at or above the threshold at which APLAR would test and at or above the African American prevalence at which the ACR does test.
What does not exist is the evidence that would close the argument. There is no published Indian case-control study of HLA-B*58:01 and allopurinol-induced severe cutaneous reactions, no Indian carrier frequency measured in gout patients rather than stem cell donors, and no Indian cost-effectiveness analysis. The frequency is known; the drug-reaction association in Indians and the value of screening are not. This tool reports the frequency for the patient's region and leaves the decision explicitly with the clinician, because that is the honest state of the evidence.
10. Febuxostat: Two Trials Pointing in Opposite Directions
CARES randomised 6,190 gout patients, all with established cardiovascular disease, to febuxostat or allopurinol over a median of 32 months. The composite of major adverse cardiovascular events was non-inferior, but cardiovascular death was higher on febuxostat, 134 against 100 deaths, hazard ratio 1.34 with a confidence interval from 1.03 to 1.73, and all-cause death was higher too, hazard ratio 1.22. That produced the American boxed warning that remains in force.
FAST then randomised 6,128 patients over a median of about four years and found the opposite direction: the primary cardiovascular composite gave a hazard ratio of 0.85 on treatment, cardiovascular death 0.91, and all-cause mortality actually favoured febuxostat at 0.75. The authors concluded non-inferiority. The differences usually invoked are that CARES was double blind with 100 per cent established cardiovascular disease and used 40 to 80 mg, while FAST was open-label with blinded endpoints, about a third with established disease, and used 80 to 120 mg. Both had heavy discontinuation, and febuxostat withdrawal in FAST was double that of allopurinol.
Regulators have not converged. The FDA retains its boxed warning. The European product information, which advised avoidance in 2019, now advises caution with regular monitoring after FAST. The ACR sits between the two and conditionally recommends switching a patient with cardiovascular disease off febuxostat to an alternative. A teaching slide that says "Europe says avoid febuxostat" is out of date; one that says the question is settled in either direction is wrong.
11. The Interaction That Causes Marrow Failure
Azathioprine is converted to 6-mercaptopurine, which is inactivated largely by xanthine oxidase. Block that enzyme with allopurinol or febuxostat and the thiopurine is diverted into the active nucleotide pathway, producing profound and sometimes fatal myelosuppression. This is not a theoretical interaction and it is not mild.
The instructions differ by drug and the difference runs opposite to intuition. The allopurinol label permits the combination with the azathioprine dose reduced to one third to one quarter of usual, with intensive blood count monitoring. The American febuxostat label makes azathioprine and mercaptopurine an outright contraindication; the European label calls it not recommended and, if unavoidable, requires the thiopurine at 20 per cent or less of the previous dose. So a clinician who switches from allopurinol to febuxostat because the patient is on azathioprine has the interaction exactly backwards. In an Indian transplant unit where azathioprine is still used for cost reasons, the safer route is usually to move the immunosuppression to mycophenolate rather than to manoeuvre around the interaction.
12. Pyrazinamide, and the Urate That Does Not Need Treating
Pyrazinamide inhibits tubular secretion of urate, and the World Health Organization product information classifies hyperuricaemia on it as very common, meaning at least one in ten, with arthralgia and gout episodes common, between one in a hundred and one in ten. A prospective series measured the mean urate rising from 5.1 mg/dL before treatment to 7.4 mg/dL by week 8, with hyperuricaemia in 43 per cent and arthralgia in 21.7 per cent.
Three points follow, and all three are commonly got wrong on Indian wards. First, the threshold at which the product information asks for any corrective treatment is 11 mg/dL, which means an asymptomatic urate of 8, 9 or 10 during anti-tubercular treatment needs no drug and is not a reason to stop pyrazinamide. Second, when correction is indicated the same document explicitly excludes xanthine oxidase inhibitors, because the lesion is blocked tubular secretion rather than overproduction, so allopurinol does not fix it. Third, moderate non-gouty arthralgia responds to symptomatic treatment and resolves; only persistent arthralgia that genuinely appears gouty justifies stopping the drug. Ethambutol also raises urate, but the primary sources for its mechanism and magnitude could not be obtained for this module, so no figure is given for it here.
13. The Dal Question
A vegetarian patient with gout in an Indian clinic is very often told to stop dal, rajma, spinach and mushrooms. The prospective evidence does not support that advice. In 47,150 men followed for 12 years with 730 confirmed incident cases of gout, the multivariate relative risk for the highest against the lowest quintile was 1.41 for total meat and 1.51 for seafood, while purine-rich vegetables showed no significant association and total protein showed none either. The exposure labelled purine-rich vegetables in that study is precisely peas, beans, lentils, spinach, mushrooms and cauliflower. APLAR, with Indian authors on the panel, states that there is insufficient evidence to recommend for or against limiting purine-rich food to prevent flares.
What the same cohorts do show is where the modifiable risk actually sits. Sugar-sweetened soft drinks carried a relative risk of 1.85 at two or more servings a day and free fructose 2.02 in the highest fifth, while diet soft drinks showed nothing at all. Fruit juice at two or more glasses daily carried 1.81, which is the finding patients and residents most often have backwards, because juice is culturally coded as healthy. Alcohol is dose-dependent and beverage-specific: per daily serving, beer 1.49, spirits 1.15, and wine 1.04, which was not significant. Dairy runs the other way and is protective, 0.56 for total dairy and 0.58 for low-fat dairy, with high-fat dairy neutral. Coffee is protective in a dose-dependent way, 0.60 at four to five cups daily and 0.41 at six or more, with a smaller effect for decaffeinated coffee and none for tea or for total caffeine, which points to something in coffee other than caffeine.
So the honest counselling for an Indian vegetarian patient is: keep the dal, which is the main protein in the diet and carries a real nutritional cost if removed; add curd, buttermilk and low-fat milk, which are protective; stop the soft drinks and the daily fruit juice; and understand that none of this substitutes for reaching a serum urate below 6 mg/dL, which diet alone will not do. Vitamin C supplementation is conditionally recommended against by the ACR and does not lower urate to a clinically useful degree.
14. Tumour Lysis: the Sample on Ice, and G6PD
Laboratory tumour lysis is defined by two or more of a urate of 8.0 mg/dL or above, potassium 6.0 mmol/L or above, phosphate 4.5 mg/dL or above in adults, or calcium 7.0 mg/dL or below, within the same 24 hours, from three days before to seven days after starting treatment, each also satisfiable by a 25 per cent change from baseline. Clinical tumour lysis adds a creatinine above 1.5 times the age-adjusted upper limit, a seizure, or an arrhythmia or sudden death. The 2011 Howard modification removed the 25 per cent rule altogether, on the ground that a 25 per cent rise within the normal range is not pathological, so a patient may meet one definition and not the other.
Allopurinol blocks the formation of new urate and does nothing to the urate already circulating; it also causes xanthine to accumulate, which has its own nephropathy. Rasburicase degrades urate that is already there. The licensed dose is 0.2 mg/kg intravenously over 30 minutes daily for up to five days, which in India costs roughly 36,000 rupees a day. Two Indian institutional series have published a single fixed dose of 1.5 mg instead, at roughly 6,000 rupees: in 186 patients at Chennai it prevented laboratory or clinical tumour lysis in 87 per cent of the prophylactic group, and in 90 patients at Bengaluru 60 per cent normalised on 1.5 mg alone with a further 18 per cent on a second dose. That is a defensible, published, resource-adapted regimen and this tool prints it alongside the licensed one.
Two hard rules. Rasburicase is contraindicated in G6PD deficiency, because the reaction generates hydrogen peroxide and produces acute haemolysis and methaemoglobinaemia. Indian G6PD deficiency prevalence in tribal populations runs from 2.3 to 27.0 per cent with an overall figure of 7.7 per cent across 72 tribal groups, and no reliable general-population figure was found; in tribal-belt hospitals this is an operational problem rather than a formality, and the assay usually does not return within the window in which the drug is needed. And after rasburicase, any blood for uric acid must be drawn into a pre-chilled heparin tube, kept in iced water and assayed within four hours, because the enzyme keeps degrading urate in the tube. A normal result from a warm sample is meaningless and falsely reassuring.
Urinary alkalinisation for tumour lysis has been abandoned. It increases calcium phosphate precipitation and reduces xanthine solubility, and every current protocol consulted for this module states it is no longer recommended. Hydration is the intervention that matters: 2 to 3 litres per square metre per day, targeting a urine output above 100 mL per square metre per hour.
15. Uric Acid Stones Are a Disease of Acid Urine
Aciduria, not hyperuricosuria, is the dominant factor. Uric acid has a pKa of about 5.3 to 5.5, sources vary, so below pH 5.5 most of the urinary urate exists as undissociated uric acid, which is very much less soluble than the salt. The arithmetic is worth carrying: of an 800 mg daily uric acid load, about 600 mg is undissociated at pH 5.0, and only about 100 mg at pH 6.5.
The targets differ by purpose and the guidelines differ with them. For prevention the American Urological Association says raise urine pH to 6.0; for active dissolution of an existing stone the European Association of Urology says 7.0 to 7.2. Above pH 7.0 solubility does not improve further and calcium phosphate precipitation begins, so over-alkalinisation converts one kind of stone former into another. Potassium citrate is the preferred salt at 30 to 60 mEq daily in divided doses, contraindicated in hyperkalaemia and in significant renal impairment; sodium bicarbonate is the alternative in advanced kidney disease, at the cost of a sodium load and higher urinary calcium.
Allopurinol is not first-line for a uric acid stone. It is indicated where 24-hour urinary uric acid is genuinely high, above 800 mg daily in men and 750 in women by the American convention, or above 5 and 4 mmol daily respectively by the European one, which is a real numerical disagreement between the two. One India-specific caution: the citrate preparations on Indian wards are syrups dosed in millilitres, while every guideline dose is in milliequivalents of citrate. Without reading the citrate content per millilitre off the specific product, a resident cannot reproduce the recommended dose, and this tool cannot supply that figure for any particular Indian brand.
16. Indian Epidemiology, and an Unresolved Discordance
Community surveys put gout prevalence in India remarkably low. Household surveys around Pune found an age and sex adjusted prevalence of 0.06 per cent in an urban population of 8,145 adults and 0.13 per cent in a rural one, against a worldwide range of 0.26 to 1.4 per cent. Yet biochemical surveys find hyperuricaemia everywhere: 24.66 per cent of 197,097 subjects across 592 Indian screening locations, and 32.7 per cent of 300 adults screened in rural Belagavi.
Those two sets of numbers are hard to reconcile, and no source consulted for this module resolves them. It may be genuine biology, or under-diagnosis of gout in Indian primary care, or the difference between a screening questionnaire and a blood test, or selection into camp and screening cohorts. It is presented here as an open question rather than smoothed over, because whichever explanation is right changes what a physician should do with a raised urate in an Indian clinic. Note also that there is no Indian national guideline or professional society consensus statement on gout or hyperuricaemia: a 2023 systematic review of high-quality gout guidelines included six, from Europe, the United States, Italy, Britain and Spain, and none from India. The closest applicable document with Indian authorship is the APLAR 2021 guideline, which this tool cites for that reason.
17. What This Tool Deliberately Does Not Do
It does not decide whether to treat asymptomatic hyperuricaemia. That was a deliberate editorial choice: it places the patient against each guideline and prints what each would do, because there is no consensus to hand down and pretending otherwise would be the more confident error. It does not classify calcium pyrophosphate deposition disease, although it will say when the pattern fits and point you elsewhere. It does not give a pegloticase dose, because that agent could not be confirmed as obtainable in India. It does not give an intravenous methylprednisolone dose for a flare, because no guideline consulted contains one. It does not stage chronic kidney disease, which is what the renal staging module is for, and it does not adjust any antimicrobial, which is what the dosing module is for. And it does not aspirate the joint, which remains the only thing that actually makes the diagnosis.
Algorithm References & Evidence Base
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744-760.
- Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.
- Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38.
- Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557-2568.
- Janssens HJEM, Fransen J, van de Lisdonk EH, van Riel PLCM, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120-1126.
- Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58-68.
- Lorenzo JPP, Sollano MHZ, Salido EO, et al. 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. Int J Rheum Dis. 2021. doi:10.1111/1756-185X.14266. Two of the panel members are Indian rheumatologists, and this is the guideline with Indian authorship that comes closest to a national document.
- Japanese Society of Gout and Uric & Nucleic Acids. Guideline for the management of hyperuricaemia and gout, 3rd edition, with the 2022 supplement. Thresholds and graded clinical questions read from the official summary in the Minds Guideline Library of the Japan Council for Quality Health Care. The primary Japanese document itself was not obtainable for this module.
- Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases. Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases. Chin Med J (Engl). 2017.
- Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-1528.
- Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare. Arthritis Rheum. 2010;62(4):1060-1068.
- Ramasamy SN, Korb-Wells CS, Kannangara DRW, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36(10):953-980.
- White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-1210.
- Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745-1757.
- Mackenzie IS, Hughes D, Ford I, et al. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART randomised controlled trial and economic evaluation. Health Technol Assess. 2024.
- Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504-2513.
- Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-1103.
- Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-312.
- Solloch UV, Schefzyk D, Schäfer G, et al. HLA allele and haplotype frequencies of eight Indian populations based on 130,518 registered stem cell donors. Front Immunol. 2025;16:1528177.
- Philips A, Radhakrishnan V, Ganesan P, et al. Efficacy of single dose rasburicase (1.5 mg) for prophylaxis and management of laboratory tumor lysis syndrome. Indian J Hematol Blood Transfus. 2018;34(4):618-622.
- Lakshmaiah KC, Jacob LA, Suresh Babu MC, et al. Efficacy of a reduced-dose rasburicase: single-institution experience in India. Indian J Med Paediatr Oncol. 2019;40(3):406-408.
- Mukherjee MB, Colah RB, Martin S, Ghosh K. Glucose-6-phosphate dehydrogenase (G6PD) deficiency among tribal populations of India: country scenario. Indian J Med Res. 2015;141(5):516-520.
- Misra DP, Sharma A, Dharmanand BG, Chandrashekara S. The epidemiology of rheumatic diseases in India. Indian J Rheumatol. 2024;19(1):54-61.
- World Health Organization. Product information for pyrazinamide 500 mg tablets. WHO Prequalification of Medicines Programme, WHOPAR part 4. The source for the frequency of hyperuricaemia on pyrazinamide, the 11 mg/dL threshold for corrective treatment, and the exclusion of xanthine oxidase inhibitors from that treatment.
Drug doses in this module are taken from prescribing information rather than from guidelines wherever the guidelines do not state a dose, which is the case for every corticosteroid, every NSAID and both interleukin-1 blockers. The colchicine, allopurinol, febuxostat, methylprednisolone acetate, rasburicase, azathioprine and potassium citrate labels, the American Urological Association and European Association of Urology stone guidelines, and the Indian prescribing information for allopurinol and febuxostat, are cited in the result panel at the point where each figure is used.
How to Cite This Tool
AMA Style:
Umakanth S. Hyperuricaemia and Gout Pathway. MEDiscuss. Published 2026. Accessed .
Vancouver Style:
Umakanth S. Hyperuricaemia and Gout Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:
Save this calculation
Whatever you type here stays on this device and is not sent anywhere. The server receives only a scrambled code made from it, so nobody with access to the server can tell which patient a saved calculation belongs to. Enter the same nickname the next time to see that patient's earlier values. What is stored
Last revised: 21 August 2026